Elanco Animal Health has acquired the former GM Stamping Plant site in Indianapolis for $27 million, as Indiana's push for economic expansion gains traction. Indiana Gov. Mike Braun made the announcement on Aug. 25, marking a substantial step forward in the city's redevelopment efforts. According to WTHR, the site will serve as the innovative new home for Elanco, enhancing Indianapolis' role in the global life sciences sector.
Executives from the company have outlined a vision that encapsulates more than just a corporate headquarters. Indeed, the grand scheme is a fusion of research facilities, pilot-scale operations, and clinical care, all nestled within a community-centric environment offering housing, retail, and green spaces. The area is positioned to become a hub for innovation. WANE highlighted this transformative intent. with officials aiming to elevate the district to a status of global relevance in the area of One Health.
The investment by Elanco, a former subsidiary of Eli Lilly and Company specializing in veterinary medicine, is anticipated to catalyze job creation and foster long-term economic growth within the state. As reported by WIBC, leaders from both the private and public sectors expect this initiative to significantly benefit Indiana's workforce and innovation landscape.
At the heart of the project is a partnership that extends beyond traditional corporate-state dynamics. "This is about partnership and progress," Jeff Simmons, the CEO of Elanco Animal Health, stated emphatically. "The state’s willingness to work with us—not as a landowner but as a partner—makes this possible. Securing this property now gives us the certainty we need to integrate it into our headquarters campus and move forward with speed," Simmons told WANE. He further expressed excitement for the company's imminent move in early October and the positive ripple effects to follow.
